[go: up one dir, main page]

LV15783A - Novel pyruvate kinase isoform m2 inhibitors - Google Patents

Novel pyruvate kinase isoform m2 inhibitors

Info

Publication number
LV15783A
LV15783A LVP-22-34A LVP2022000034A LV15783A LV 15783 A LV15783 A LV 15783A LV P2022000034 A LVP2022000034 A LV P2022000034A LV 15783 A LV15783 A LV 15783A
Authority
LV
Latvia
Prior art keywords
pyruvate kinase
inhibitors
kinase isoform
novel
novel pyruvate
Prior art date
Application number
LVP-22-34A
Other languages
Latvian (lv)
Inventor
Pāvels ARSENJANS
Pāvels DIMITRIJEVS
Marina MAKRECKA-KŪKA
Original Assignee
Latvijas Organiskās Sintēzes Institūts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Latvijas Organiskās Sintēzes Institūts filed Critical Latvijas Organiskās Sintēzes Institūts
Priority to LVP-22-34A priority Critical patent/LV15783A/en
Priority to PCT/IB2022/061762 priority patent/WO2023203374A1/en
Priority to DE112022006813.2T priority patent/DE112022006813T5/en
Priority to CA3246846A priority patent/CA3246846A1/en
Publication of LV15783A publication Critical patent/LV15783A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D517/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D517/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms in which the condensed system contains two hetero rings
    • C07D517/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Šis izgudrojums attiecas uz jauniem izoselenazolopiridīnija sāļiem kā pretvēža līdzekļiem, kas inhibē piruvātkināzes M2 izoformas (PKM2) aktivitāti, kā arī uz to iegūšanas metodēm un izmantošanu dažādās zāļu formās vairāku slimību un veselības traucējumu ārstēšanai, lietojot šādas vielas.This invention relates to novel isoselenazolopyridinium salts as anticancer agents that inhibit the activity of pyruvate kinase M2 isoform (PKM2), as well as to methods of their preparation and use in various dosage forms for the treatment of several diseases and health disorders using such agents.

LVP-22-34A 2022-04-20 2022-04-20 Novel pyruvate kinase isoform m2 inhibitors LV15783A (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
LVP-22-34A LV15783A (en) 2022-04-20 2022-04-20 Novel pyruvate kinase isoform m2 inhibitors
PCT/IB2022/061762 WO2023203374A1 (en) 2022-04-20 2022-12-05 [1,2]selenazolo[2,3-a]pyridin-8-ium inhibitors of pyruvate kinase isoform m2
DE112022006813.2T DE112022006813T5 (en) 2022-04-20 2022-12-05 [1,2]SELENAZOLO[2,3-A]PYRIDINE-8-IUM INHIBITORS OF PYRUVATE KINASE ISOFORM M2
CA3246846A CA3246846A1 (en) 2022-04-20 2022-12-05 [1,2]selenazolo[2,3-a]pyridin-8-ium inhibitors of pyruvate kinase isoform m2

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LVP-22-34A LV15783A (en) 2022-04-20 2022-04-20 Novel pyruvate kinase isoform m2 inhibitors

Publications (1)

Publication Number Publication Date
LV15783A true LV15783A (en) 2023-10-20

Family

ID=81579876

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-22-34A LV15783A (en) 2022-04-20 2022-04-20 Novel pyruvate kinase isoform m2 inhibitors

Country Status (4)

Country Link
CA (1) CA3246846A1 (en)
DE (1) DE112022006813T5 (en)
LV (1) LV15783A (en)
WO (1) WO2023203374A1 (en)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARSENYAN PAVEL ET AL: "Fused Selenazolinium Salt Derivatives with a Se-N + Bond: Preparation and Properties : Fused Selenazolinium Salt Derivatives", EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, vol. 2015, no. 26, 4 August 2015 (2015-08-04), DE, pages 5842 - 5855, XP055975213, ISSN: 1434-193X, DOI: 10.1002/ejoc.201500582 *
MAKRECKA-KUKA MARINA ET AL: "Fused isoselenazolium salts suppress breast cancer cell growth by dramatic increase in pyruvate-dependent mitochondrial ROS production", SCIENTIFIC REPORTS, vol. 10, no. 1, 1 December 2020 (2020-12-01), XP055975208, Retrieved from the Internet <URL:https://www.nature.com/articles/s41598-020-78620-8.pdf> DOI: 10.1038/s41598-020-78620-8 *

Also Published As

Publication number Publication date
WO2023203374A1 (en) 2023-10-26
DE112022006813T5 (en) 2024-12-24
CA3246846A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
MX2023007192A (en) PRMT5 INHIBITORS.
MX2023009222A (en) Tricyclic-amido-bicyclic prmt5 inhibitors.
CL2023001461A1 (en) Tricyclic carboxamide derivatives as prmt5 inhibitors
CL2020002146A1 (en) N- (phenyl) -2- (phenyl) pyrimidine-4-carboxamide derivatives and related compounds as hpki inhibitors to treat cancer.
MX2021005011A (en) METHODS OF CANCER TREATMENT IN PATIENTS IDENTIFIED BY BIOMARKERS WITH NON-COVALENT INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7).
CO2021009078A2 (en) Substituted pyrazolopyrimidines and substituted purines and their use as inhibitors of ubiquitin-specific processing protease 1 (usp1)
ZA202311329B (en) Urea derivatives which can be used to treat cancer
EA202090955A1 (en) METHODS OF USING EHMT2 INHIBITORS IN TREATMENT OR PREVENTION OF BLOOD DISORDERS
EA202090052A1 (en) IMIDAZOLE-CONTAINING ALK2 KINASE INHIBITORS
EA201000341A1 (en) 2-ANILINOPURIN-8-ONE AS TTK / MPS1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS
SA522441639B1 (en) Allosteric EGFR Inhibitors and Methods of Use Thereof
EP2134346A4 (en) INHIBITORS OF JANUS KINASES AND / OR PROTEIN KINASE-1 DEPENDENT OF 3-PHOSPHOINOSITIDE
EA201892075A1 (en) COMBINATION OF LSD1 INHIBITORS FOR USE FOR THE TREATMENT OF SOLID TUMORS
EA201100391A1 (en) ACTIVITY INHIBITING SEMICARBAZID-SENSITIVE AMINOXIDASE
MX2023002324A (en) TREATMENT OF HAIR LOSS DISORDERS WITH DEUTERATED JANUS ASSOCIATED KINASE (JAK) INHIBITORS.
BR112023015210A2 (en) CDK2 INHIBITORS AND METHODS OF USE THEREOF
SA522441554B1 (en) RIPK1 isoxazolidine compounds as inhibitors and their use
EA201891931A1 (en) NEW INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE GAMMA
MX2022008627A (en) PYRAZOLO-SUBSTITUTED PYRIMIDINES AND USES THEREOF.
BR112021022602A2 (en) Methods for treating chronic spontaneous urticaria with the use of a bruton tyrosine kinase inhibitor
EA202191955A1 (en) MODIFIED RELEASE TABLET FORMULATIONS CONTAINING PHOSPHODIESTERASE INHIBITORS
JOP20200100A1 (en) Pyrazolo-pyrrolo-pyrimidine-diene derivatives are new as P2X3 inhibitors
GEAP202416449A (en) Compounds that inhibit pi3k isoform alpha and methods for treating cancer
MX2022000390A (en) Macrocyclic spirocycle derivatives as mcl-1 inhibitors.
MX2023013538A (en) Methods of treating depression and anxiety.